Neuronetics Receives 510(k) Clearance for NeuroSite™ Coil Placement Accessory
Neuronetics, Inc. (NASDAQ: STIM) announced the FDA 510(k) clearance of NeuroSite™ Coil Placement Accessory, a tool that simplifies measurement and coil positioning during NeuroStar TMS treatments. The accessory integrates with both legacy and new NeuroStar systems, streamlining the TMS process with significantly fewer patient setup steps, improving efficiency for providers and enhancing the patient experience. NeuroSite™ will be available to all NeuroStar providers beginning in Q1 of 2024.
Positive
FDA 510(k) clearance of NeuroSite™ Coil Placement Accessory
Seamless integration with both legacy and new NeuroStar systems
Streamlining the TMS process with significantly fewer patient setup steps
Improving efficiency for providers’ offices and patient experience
Precise and reproducible coil placement ensuring accuracy
Availability to all NeuroStar providers beginning in Q1 of 2024
12/18/2023 - 08:49 AM
New accessory for NeuroStar TMS reduces patient setup steps and improves efficiency for providers
MALVERN, Pa., Dec. 18, 2023 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM), a medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from neurohealth disorders, announced the U.S. Food and Drug Administration 510(k) clearance of NeuroSite™ Coil Placement Accessory, a state-of-the-art tool that simplifies measurement and coil positioning during NeuroStar transcranial magnetic stimulation (TMS) treatments. This proprietary accessory, designed with versatility and provider convenience in mind, seamlessly integrates with both legacy and new NeuroStar systems and further enhances efficiency and patient experience.
“The NeuroSite™ FDA clearance is the latest of many enhancements designed to improve the patient experience, exemplifying our ongoing commitment to continually advance medical technology for mental health,” stated Cory Anderson, SVP of R&D and Clinical. “We are thrilled to introduce yet another innovative accessory to our suite of products that deliver a fast, easy, reliable treatment that both patients and providers trust.”
By leveraging the patient's unique anatomical features, NeuroSite™ Coil Placement Accessory ensures precise and reproducible coil placement. This streamlines the NeuroStar TMS process with significantly fewer patient setup steps1 , thereby improving efficiency for providers’ offices and improving the patient experience while maintaining the accuracy established by the current NeuroStar Head Support System (HSS).
“As a NeuroStar TMS provider with multiple systems, I appreciate how user-friendly NeuroSite™ is, along with the flexibility it brings to patient positioning across all generations of NeuroStar devices,” said Dr. Kenneth Pages, Medical Director at TMS of South Tampa. “This latest tool reinforces my confidence in providing consistent results and truly exceptional care to my patients.”
NeuroSite™ will be available to all NeuroStar providers beginning in Q1 of 2024. For more information about NeuroStar TMS Therapy, please visit NeuroStar.com .
About Neuronetics Neuronetics, Inc. believes that mental health is as important as physical health. As a global leader in neuroscience, Neuronetics is redefining patient and physician expectations with its NeuroStar Advanced Therapy for Mental Health. NeuroStar is a non-drug, noninvasive treatment that can improve the quality of life for people suffering from neurohealth conditions when traditional medication hasn’t helped. In the United States, NeuroStar is FDA-cleared for adults with major depressive disorder (MDD), as an adjunct for adults with obsessive-compulsive disorder (OCD), and to decrease anxiety symptoms in adult patients with MDD that may exhibit comorbid anxiety symptoms (anxious depression). NeuroStar Advanced Therapy is the leading transcranial magnetic stimulation (TMS) treatment for MDD in adults with over 5.9 million treatments delivered. NeuroStar is backed by the largest clinical data set of any TMS system for depression, including the world’s largest depression Outcomes Registry. Neuronetics is committed to transforming lives by offering an exceptional treatment that produces extraordinary results. For safety and prescribing information, www.neurostar.com .
Media Contact: EvolveMKD 646.517.4220NeuroStar@evolvemkd.com
1 Data on file, Neuronetics 2023
What is the FDA 510(k) clearance for NeuroSite™ Coil Placement Accessory?
The FDA 510(k) clearance allows NeuroSite™ Coil Placement Accessory to be marketed and used in the United States.
How does NeuroSite™ improve efficiency for providers?
NeuroSite™ streamlines the TMS process with significantly fewer patient setup steps, improving efficiency for providers’ offices.
When will NeuroSite™ be available to NeuroStar providers?
NeuroSite™ will be available to all NeuroStar providers beginning in Q1 of 2024.
What are the benefits of NeuroSite™ for patient experience?
NeuroSite™ ensures precise and reproducible coil placement, improving the patient experience while maintaining accuracy.
What are the key features of NeuroSite™?
NeuroSite™ is designed with versatility and provider convenience in mind, seamlessly integrating with both legacy and new NeuroStar systems, and bringing flexibility to patient positioning across all generations of devices.
STIM Rankings
#5101 Ranked by Stock Gains
STIM Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Health Technology, Medical Specialties, Manufacturing, Surgical and Medical Instrument Manufacturing
Country
US
City
Malvern
About STIM
with neurostar advanced therapy, neuronetics, inc., is the market leader in transcranial magnetic stimulation technology for the treatment of major depressive disorder. based in malvern, pa, we are a privately held medical device company focused on developing non-invasive therapies for psychiatric and neurological disorders using mri-strength magnetic field pulses. we are the first company to have a non-systemic and non-invasive depression treatment cleared by the fda for patients who have not benefited from prior antidepressant medication. neuronetics markets neurostar advanced therapy throughout the united states and select markets around the world. if you have questions or comments about neurostar, please e-mail us at customersupport@neuronetics.com. for u.s. phone support, please call us at (877) 600-7555, for international customers, our number is +1 (610) 640-4207.